Focused On-demand Library for Electrogenic aspartate/glutamate antiporter SLC25A12, mitochondrial

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O75746

UPID:

S2512_HUMAN

Alternative names:

Araceli hiperlarga; Mitochondrial aspartate glutamate carrier 1; Solute carrier family 25 member 12

Alternative UPACC:

O75746; B3KR64; Q96AM8

Background:

The Electrogenic aspartate/glutamate antiporter SLC25A12, mitochondrial, also known as Mitochondrial aspartate glutamate carrier 1 and Araceli hiperlarga, plays a crucial role in mitochondrial function. It facilitates the exchange of aspartate and glutamate across the mitochondrial membrane, integral to the malate-aspartate shuttle, a key process in cellular energy production.

Therapeutic significance:

SLC25A12's involvement in Developmental and epileptic encephalopathy 39 with leukodystrophy, a severe early-onset epilepsy, underscores its therapeutic potential. Targeting this protein could lead to novel treatments for this and related neurological disorders.